Another relevant experimental study demonstrated that VEGFR-2 antibody treatment led to intratumoral immunomodulation and enhanced the antitumor efficacy of PD-L1 blockers in a homozygous mouse tumor model (Li et al. 2022). This evidence concerns the gene KDR and neoplasm.